Trial Profile
A Phase 2, Open-label, Prospective, Multicenter Study to Evaluate the Efficacy of Intravenous Busulfan and Melphalan as a Conditioning Regimen in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Busulfan (Primary) ; Melphalan (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 19 Aug 2013 New trial record